Streamex heads into its September-quarter report with a simple problem: the market has stopped giving it the benefit of the doubt. Shares of the former BioSig Technologies, now rebuilt around tokenizing gold and other commodities on blockchain rails, have fallen about 65% since the last report, trailing the S&P 500 by roughly 60 percentage points. For a company still at the very start of its commercial life, this release is less about a penny or two of earnings and more about whether there is a business forming underneath the story.

Wall Street is looking for a loss of 3 cents a share on revenue of about $300,000. That would be a sharp improvement from the 8-cent loss last quarter and from the 47-cent loss a year earlier, which works out to an expected improvement of roughly 94% year over year. Revenue matters more here. Last quarter brought in about $0.1 million, so consensus implies sales roughly tripling sequentially. That is a large jump in percentage terms on a very small base. Hitting it would be the first real sign that the tokenization platform is drawing paying activity. Missing it would suggest the model is still mostly a concept. One caution on the per-share figures: for an early-stage company, a narrower loss per share can come from tighter spending, but it can also come partly from a larger share count. The absolute loss and cash usage will tell readers more than the EPS line.

Without formal guidance to anchor the numbers, the report itself will have to set the narrative. The most useful evidence would be concrete measures of adoption. That means the value of assets brought on chain, the number of institutional counterparties using the platform, and whether revenue looks recurring rather than one-time. Management's account of how this business makes money will also matter, whether through issuance fees, custody, trading activity, or something else, because the market has little history to go on. Any update on the company's cash position and funding runway will draw close scrutiny, since an operation at this stage depends on capital to keep building infrastructure until revenue can carry costs.

Sentiment confirms how low the bar has fallen. Earnings Whispers readings sit at about 22% bearish, and the chart tells the same story. At $0.34, the stock trades far below its 200-day moving average of $1.19 and only about 10% above its post-earnings low of $0.31. The range since the last report, $0.31 to $1.00, sits entirely below the prior quarter's $0.66 to $1.61 band. That pattern points to steady distribution rather than a single bad day. Heavy pessimism can set up a relief move if the numbers show tangible progress. It also means a disappointment could push shares into new lows with little support nearby.

The key question is whether Streamex can show that tokenized commodities are producing revenue at a pace that justifies the cost of building the platform. Revenue near or above $300,000, paired with clear adoption metrics and a credible funding picture, would give the bull case something solid to stand on. Flat sales, vague operating disclosures, or signs that cash is running short would reinforce the market's view that the pivot from medical devices to on-chain gold is still more promise than proof.